Actos/Actoplus Met/Actoplus Met XR/Duetact Drug Injury
Actos, Actoplus Met, Actoplus Met XR, and Duetact are a set of pioglitazone drugs designed and marketed to combat the effects of Type 2 Diabetes. Pioglitazone works to increase the body’s sensitivity to insulin, decreasing the amount of glucose released by the liver, but avoiding hypoglycemia (low blood sugar) by not stimulating insulin production to offset it. It was established in 2011 and confirmed by the Food and Drug Administration that long-term use of pioglitazone drugs, including Actos, Actoplus Met, Actoplus Met XR, and Duetact, is linked to the onset of bladder cancer. The medical reason for this link is under study, and the FDA did not pull these drugs from the shelf but did recommend that they not be prescribed to any patients with active bladder cancer or with any history of bladder cancer or other bladder-related illness. Takeda Pharmaceuticals and Eli Lilly, the companies that market Actos, Actoplus Met, Actoplus Met XR, and Duetact did nothing to warn consumers about the possible implications of the use of its pioglitazone treatments for Type 2 Diabetes; the companies did not even update the drugs’ black box labels. A number of lawsuits relating to pioglitzones’ relationship to bladder cancer in Type 2 diabetics have been filed and ended with successful settlements. These suits have focused on the negligence of the makers of these drugs in manufacturing a potentially dangerous product, failing to properly test or publish data relating to the drugs’ dangerous side effects, and concealing knowledge about the possible effects of prolonged pioglitazone intake. If you or a loved one was prescribed Actos, Actoplus Met, Actoplus Met XR, and/or Duetact and after taking the drug(s) for over a year fell victim to bladder cancer, you could be entitled to compensation. Benefits may be available to help cover costs of medical expenses, funeral expenses, lost wages, and pain and suffering.
Grimes Teich Anderson LLP advocates for the victims of corporate and government oversights. If you have been forced to battle bladder cancer after taking a Type 2 Diabetes medication utilizing pioglitazone, you need an experienced team dedicated to supporting you and your needs to help you get the benefits to which you are entitled. Grimes Teich Anderson attorneys have extensive experience in fighting the actions of greedy corporations, and are ready to help you.
It is almost impossible to win a case against a major pharmaceutical corporation alone, as companies have the resources and financial interest to hire full-scale legal teams to make sure they pay you as little as possible. Attempting to handle your case alone will likely result in a settlement of far less value than what you actually need and deserve. Similarly, working to address your needs alone may cause you to nullify your own legal rights simply through a lack of knowledge about the complex inner workings of the U.S. code as it applies to medical and pharmaceutical cases.
Let our teams of experienced attorneys and researchers take on your case so that you get all that you need to cover your expenses. Your experience with bladder cancer resulting from prolonged consumption of Actos, Actoplus Met, Actoplus Met XR, or Duetact is not your fault, and we are here to help you in any way we can.FREE CASE EVALUATION
If you or someone you love dealt with bladder cancer after taking Type 2 pioglitazone drugs, you could be eligible for compensation for your medical expenses, pain and suffering, and lost wages, as well as the punitive damages to which you could be entitled because Takeda Pharmaceuticals and/or Eli Lilly failed to inform consumers of the potential dangers of their products. If you fit this description, get in touch with Grimes Teich Anderson LLP today at (800) 533-6845 to request a free consultation with an experienced drug injury attorney. For your convenience, you can also opt to submit a free case evaluation form online.
Grimes Teich Anderson LLP has law offices located in Spartanburg, Greenville, and Gaffney, South Carolina and Asheville, Waynesville, Rutherfordton, Spruce Pine, and Franklin, North Carolina.